At BELLUS, we are focused on developing novel therapeutics for conditions with high unmet medical need. Read More

On November 19, 2018, BELLUS announced the positive top-line results from the clinical Phase 1 study for BLU-5937, its lead drug candidate for chronic cough. Read More


March 29, 2018 What a Difference Another Year Makes
(From the 2017 Annual Report)   Dear Shareholders, We are a little more than one year into our new business plan focused on BLU-5937 for chronic cough. I would like to tell you about the feedback we’ve received to date and how 2018 is shaping into a milestone year as we enter our first in-human studies. Positive Feedback When we first in-licensed BLU-5937 in February 2017, we vetted the...
Read More
February 9, 2018 BELLUS Health in a Volatile Market
Watching the markets fluctuate over the last few days, I am very grateful that we completed a $20M financing in December that: increased our cash runway to two+ years and through multiple important business milestones; included a wide spectrum of investors which diversifies our shareholder base involved significant participation from validating investors, including insiders and sophisticated...
Read More

Share this

Sign up for email alerts

Email Address *
Enter the code shown above.